Exendin-4 for Parkinson's disease
Open accessAbstract
This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Exenatide, an agonist of GLP-1 receptor, showed protective effects in PD patients in a Phase II clinical trial.
“In a Phase II clinical trial, exenatide, an agonist of the GLP-1 receptor, showed great protective effects in PD patients.572”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [572]
The “Exendin-4 in Parkinson’s Disease Patients” section (page unavailable) reports modest motor improvements in exenatide-treated patients and says persistent improvement suggests it may modify disease progression. It does not identify either trial as Phase II, and its cautious findings do not establish the claimed great protective effects in patients. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 2× · see citing works
“The first clinical trial entailed a double‐blind randomized study of self‐administered exenatide or placebo in 62 participants over 48 weeks of treatment then followed by a 12‐week washout interval.[16] The second clinical trial involved a single‐blinded randomized study over a 12‐month period of self‐administered exe…”
BackgroundMethodExenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529 · see citing works
Kim, D. S., Choi, H.-I., Wang, Y., Luo, Y., Hoffer, B. J., & Greig, N. H. (2017) · Cell Transplantation · doi:10.1177/0963689717721234 · Cited by 136 · see citing works
Flagged first, then by citations
Research works printed but not linked: 17
- [1]Durieux PF Schiffmann SN de Kerchove DA Targeting neuronal populations of the striatum Front Neuroanat 2011 5 40 21811438 PMC3139926
- [2]Gerfen CR Surmeier DJ Modulation of striatal projection systems by dopamine Annu Rev Neurosci 2011 34 441 66 21469956 PMC3487690
- [3]Nambu A Tokuno H Takada M Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway Neurosci Res 2002 43 111 7 12067746
- [4]Petri D Pum M Vesper J Huston JP Schnitzler A GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat Behav Brain Res 2013 252 58 67 23727148
- [5]Touchon JC Moore C Frederickson J Meshul CK Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine treated rats: Effects on striatal glutamate and apomorphine-induced contralateral rotations Synapse 2004 51 287 98 14696016
- [6]Bergman H Wichmann T DeLong MR Reversal of experimental parkinsonism by lesions of the subthalamic nucleus Science 1990 249 1436 8 2402638
- [7]Baron MS Vitek JL Bakay RA Green J McDonald WM Cole SA Treatment of advanced Parkinson's disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study Mov Disord 2000 15 230 7 10752571
- [8]Papa SM Desimone R Fiorani M Oldfield EH Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias Ann Neurol 1999 46 732 8 10553990
- [9]Merello M Balej J Delfino M Cammarota A Betti O Leiguarda R Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease Mov Disord 1999 14 45 9 9918343
- [10]Drucker DJ Mechanisms of action and therapeutic application of glucagon-like peptide-1 Cell Metab 2018 27 740 56 29617641
- [11]Gentilella R Pechtner V Corcos A Consoli A Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: Are they all the same? Diabetes Metab Res Rev 2019 35 e3070 30156747
- [12]Li Y Perry T Kindy MS Harvey BK Tweedie D Holloway HW GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism Proc Natl Acad Sci U S A 2009 106 1285 90 19164583 PMC2633544
- [14]Athauda D Foltynie T Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease Neuropharmacology 2018 136 260 70 28927992
- [15]Hölscher C Brain insulin resistance: Role in neurodegenerative disease and potential for targeting Expert Opin Investig Drugs 2020 29 333 48 32175781
- [17]Glotfelty EJ Olson L Karlsson TE Li Y Greig NH Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease Expert Opin Investig Drugs 2020 29 595 602 PMC10477949 32412796
- [18]Li Y Vaughan KL Tweedie D Jung J Kim HK Choi HI Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon Sci Rep 2019 9 17208 31748513 PMC6868133
- [20]Mulvaney CA Duarte GS Handley J Evans DJ Menon S Wyse R GLP-1 receptor agonists for Parkinson's disease Cochrane Database Syst Rev 2020 7 CD012990 32700772 PMC7390475
Cited by
Sorted by citations
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668 · see citing works
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148 · see citing works
Sango, K., Takaku, S., Tsukamoto, M., Niimi, N., & Yako, H. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.950623 · Cited by 30 · see citing works
- Authors
- Esparza-Salazar, F. D. J., Lezama-Toledo, A. R., Rivera-Monroy, G., & Borlongan, C. V.
- Affiliations
- University of South Florida (US)
- Corresponding author
- Borlongan, Cesario V.
- Venue
- Brain Circulation
- Published
- 2021-01
- Volume
- 7
- Issue
- 1
- Pages
- 41-43
- ISSN
- 2394-8108 (ISSN-L)
- PMC
- PMC8057099
- OpenAlex
- W3151452762
- Cited by
- 22
- References
- 3
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 10 · 2023: 3 · 2022: 4
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Brain Circulation (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- exendin-4, exenatide, Parkinson's disease, GLP-1 receptor agonists, insulin secretion, Parkinson's disease model, clinical trials, translational therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
